|
Indications and Dosage
Oral
Bladder spasms due to catheterisation, Dysuria, Urinary incontinence, urgency and frequency Adult: 100-200 mg 3-4 times daily. May reduce when symptoms improve.
Child: ≥12 yr Same as adult dose. |
|
Administration
May be taken with or without food.
|
|
Contraindications
Pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, GI haemorrhage, and obstructive uropathies of the lower urinary tract.
|
|
Special Precautions
Patient w/ suspected glaucoma (esp closed angle glaucoma); serious, uncontrolled, obstructive disorders of the lower urinary tract. Childn. Pregnancy and lactation.
|
|
Adverse Reactions
Nervous: Drowsiness, headache, vertigo, nervousness, mental confusion.
CV: Palpitation, tachycardia. GI: Nausea, vomiting, dry mouth/throat, abdominal pain, constipation. Resp: Reduced bronchial secretions. Genitourinary: Dysuria. Haematologic: Leucopenia, eosinophilia. Ophthalmologic: Increased intraocular tension, accommodation disturbance, blurred vision, photophobia. Dermatologic: Dryness, flushing, urticaria and other dermatoses. Others: Hyperpyrexia. |
|
Patient Counseling Information
This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
|
|
Drug Interactions
Increased CNS effects w/ other sedative agents.
|
|
Food Interaction
Increased CNS effects w/ alcohol.
|
|
Action
Description: Flavoxate is a tertiary amine w/ direct relaxant effect on smooth muscles through inhibition of phosphodiesterase, thereby reducing symptoms associated w/ bladder spasticity. It also has antimuscarinic effects.
Onset: 55 min. Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: Approx 2 hr. Metabolism: Rapidly metabolised, mainly to the active metabolite methyl flavone carboxylic acid (MFCA). Excretion: Via urine (approx 50-60%, as MFCA). |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Flavoxate, CID=3354, https://pubchem.ncbi.nlm.nih.gov/compound/Flavoxate (accessed on Jan. 21, 2020) |
|
Storage
Store between 20-25°C. Protect from light.
|
|
MIMS Class
|
|
ATC Classification
G04BD02 - flavoxate ; Belongs to the class of urinary antispasmodics.
|
|
References
Anon. Flavoxate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/03/2017. Buckingham R (ed). Flavoxate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2017. Flavoxate Hydrochloride Tablet (Epic Pharma, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/03/2017. Joint Formulary Committee. Flavoxate Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2017. McEvoy GK, Snow EK, Miller J et al (eds). Flavoxate Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 06/03/2017.
|
Sign Out
